Investigator-Assessed Progression-Free Survival (PFS)
{"Image DocumentName": "Investigator-Assessed Progression-Free Survival (PFS)", "Image ImageDescription": "Stage Ia. Stage Ib. G-Clb: Median 23.0 mo. 1-year PFS 84% R-Clb: Median 15.7 mo. 1-year PFS 63% Progression-free survival. Clb: Median 10.9 mo. 1-year PFS 27% Clb: Median 10.8 mo. 1-year PFS 27% Stratified HR: % CI: p < (log-rank) Stratified HR: % CI: p < (log-rank) On the G-Clb arm, <10% of patients had reached the median at cutoff. In contrast to the Clb arm, the G-Clb median PFS could not be reliably estimated due to the few patients at risk at time of median. Independent Review Committee-assessed PFS was consistent with investigator-assessed PFS. With permission from Goede V et al. Proc ASCO 2013;Abstract 7004.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}